Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Fred Saad(Centre Hospitalier de l’Université de Montréal), Eric J. Small(CancerCare Manitoba), Karim Fizazi(Université de Lille), Paul de Souza(St. George Hospital), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Charles J. Ryan(University of Minnesota), Youn C. Park(Janssen (United States)), Paul N. Mainwaring(Australasia Paediatric Endocrine Group), Tomasz M. Beer(Exact Sciences (United States)), Thian Kheoh(Janssen (United States)), Hendrik Van Poppel(Universitair Ziekenhuis Leuven), Scott North, John D. Hainsworth(Sarah Cannon), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Yves Fradet(Centre hospitalier universitaire de Québec), Eleni Efstathiou(The University of Texas MD Anderson Cancer Center), Evan Y. Yu(University of Washington), Thomas W. Flaig(University of Colorado Denver), Neal D. Shore(Carolina Urologic Research Center), Matthew R. Smith(Harvard University), Margaret K. Yu(Boston Biomedical (United States)), Peter F.A. Mulders(Radboud University Nijmegen), Arturo Molina(Janssen (United States)), Mary B. Todd(Janssen (United States)), Mary-Ellen Taplin(Dana-Farber Brigham Cancer Center), Celestia S. Higano(University of British Columbia), Thomas W. Griffin(Janssen (Belgium)), Joan Carles(Vall d'Hebron Hospital Universitari)

European Urology

March 6, 2014

Cited by 273

Related Papers

|Nature Genetics|2019|4.4k

|Cell|2015|3.6k

|Nature|2007|3.5k

|New England Journal of Medicine|2017|3.4k

|New England Journal of Medicine|2014|3k